3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
55
Endometrial Neoplasms
4
Polycystic Ovary Syndrome
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Recurrence
2
Neoplasms
2
Infertility
2
Carcinoma, Ductal, Breast
2
Breast Neoplasm Female
2
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Liposarcoma
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Lobular
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Female
1
Anovulation
1
Advanced Breast Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
6
Cyclophosphamide
5
pembrolizumab
3
Taxes
3
Specimen Handling
3
Doxorubicin
3
Carboplatin
3
eribulin
2
Trastuzumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
sargramostim
1
ruxolitinib
1
pertuzumab
1
onvansertib
1
olaparib
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Radiotherapy
1
Radiation
1
Panitumumab
1
Palliative Care
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Gonadotropin-Releasing Hormone
1
Exercise Test
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Inflammatory Breast Neoplasms
×
Letrozole
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled